A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech says the failure is due to a subset of undertreated patients, but the results raise the stakes for the drug, its lead product candidate, in other eye diseases.
Luminopia, a startup with a digital therapeutic for amblyopia, or lazy eye, recently published the results of a phase 3 study showing its TV-based treatment can improve vision in kids’ non-dominant eye. Patients don a headset where images are altered to make them use both eyes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AI tools for automating malaria detection, improving stroke care and predicting suicide risk are among the technologies Partners believes have the greatest potential to impact healthcare in the next year.
The organizations have announced that the first real-world clinical use of the algorithm is happening at the Aravind Eye Hospital in Madurai, India.
At CES, Bethesda, Maryland-based RightEye unveiled its new EyeQ system. The startup's EyeQ vision tests measure and analyze people's eye movements.
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.